Anemia, Hemolytic clinical trials
The registry lists 56 studies for Anemia, Hemolytic across more than 10 countries. 16 are recruiting or about to start. 16 of them are mainly about Anemia, Hemolytic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06. Counting its 12 narrower conditions too, such as Anemia, Sickle Cell: 1,966 studies, 432 open.
Get an email when these change. Save the Anemia, Hemolytic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Agios Pharmaceuticals, Inc. (5) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (4) · Assiut University (3) · Institute of Hematology & Blood Diseases Hospital, China (3) · Forma Therapeutics, Inc. (2) · Hillhurst Biopharmaceuticals, Inc. (2) · Chengdu Suncadia Medicine Co., Ltd. (2) · National Heart, Lung, and Blood Institute (NHLBI) (2)
What is being tested here
Drugs under test in Anemia, Hemolytic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 4
- Apr 2027Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease · National Heart, Lung, and Blood Institute (NHLBI)
- Jul 2027High-Dose Vitamin C in G6PDA and Pyruvate Kinase Deficiency: A Safety Study · University of Utah
- Sep 2027New CBC Parameters in Diagnosis of Hereditary Spherocytosis · Assiut University
- Oct 2027Native T1 Mapping and ECV in Chronic Hemolytic Anemia · Assiut University
Who these studies take
Of the 8 Anemia, Hemolytic studies recruiting now, 3 (38%) set no upper age limit and 4 (50%) stop at 75 or younger. 6 (75%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 4 (50%) | 4 (50%) |
| 18 | 6 (75%) | 6 (75%) |
| 30 | 6 (75%) | 6 (75%) |
| 40 | 5 (63%) | 5 (63%) |
| 50 | 5 (63%) | 5 (63%) |
| 65 | 5 (63%) | 5 (63%) |
| 75 | 4 (50%) | 4 (50%) |
| 85 | 4 (50%) | 4 (50%) |
Across all 56 studies, recruiting or not: 43% stop at 75 or younger and 36% at 65; 45% take children; 0% are for women only and 0% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
- Native T1 Mapping and ECV in Chronic Hemolytic AnemiaOct 20, 2026NCT07882303
Studies
Recruiting first, then most recently updated. Showing 50 of 56. Browse all 56 → or search them.
- Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease EndotypeRecruitingNCT07282210Phase 21 country
- A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat StudyEnrolling by invitationNCT05777993Phase 48 countries
- Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell DiseaseRecruitingNCT07566494Phase 11 country
- Native T1 Mapping and ECV in Chronic Hemolytic AnemiaNot yet recruitingNCT07882303
- New CBC Parameters in Diagnosis of Hereditary SpherocytosisNot yet recruitingNCT07842718
- A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHANot yet recruitingNCT07738822Phase 1/21 country
- A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)RecruitingNCT04901936Phase 29 countries
- Congenital Hemolytic and Dyserythropoietic AnemiasRecruitingNCT076492131 country
- High-Dose Vitamin C in G6PDA and Pyruvate Kinase Deficiency: A Safety StudyNot yet recruitingNCT07612345Phase 11 country
- A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301Enrolling by invitationNCT063637602 countries
- Predisposing Factors for Liver Diseases in Patients With Chronic Hemolytic AnemiaNot yet recruitingNCT06743854
- Study of Acquired Hemolytic Anemia in Adult Hospitalized PatientsNot yet recruitingNCT067087281 country
- Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.RecruitingNCT06655662Phase 11 country
- Post-market Clinical Monitoring of the Safety and Efficacy of the Aortic Valve BioprothesisRecruitingNCT059986941 country
- The International PNH Interest Group PNH RegistryRecruitingNCT065247261 country
- Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)RecruitingNCT012572697 countries
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of MitapivatActive, not recruitingNCT04610866Phase 1/21 country
- An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)CompletedNCT05757570Phase 1/210 countries
- A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)CompletedNCT06144749Phase 21 country
- A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) DeficiencyCompletedNCT02476916Phase 26 countries
- A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)Active, not recruitingNCT04624659Phase 317 countries
- A Study of Etavopivat in Patients With Thalassemia or Sickle Cell DiseaseCompletedNCT04987489Phase 26 countries
- Gene Therapy for Pyruvate Kinase Deficiency (PKD)CompletedNCT04105166Phase 12 countries
- Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy SubjectsCompletedNCT07040787Phase 11 country
- A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy SubjectsCompletedNCT06684041Phase 11 country
- A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy VolunteersCompletedNCT03926819Phase 11 country
- The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic AnemiaCompletedNCT05004259Phase 11 country
- A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)Active, not recruitingNCT04853576Phase 1/22 countries
- Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell TransplantationCompletedNCT03513328Phase 1/21 country
- Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO)TerminatedNCT049643235 countries
- Ferumoxytol Enhanced Hyperfine Low Field Strength MRICompletedNCT047212621 country
- Observational Study of Elizaria® in aHUS PatientsCompletedNCT047498101 country
- A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)CompletedNCT03548220Phase 316 countries
- A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)CompletedNCT03559699Phase 39 countries
- Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNHCompletedNCT04463056Phase 31 country
- SCD-PROMIS: A Software Platform to Enhance Self-efficacy and Patient-provider Engagement for Patients With Sickle Cell PainCompletedNCT03006718Not applicable1 country
- Pyruvate Kinase Deficiency Natural History StudyCompletedNCT020534806 countries
- Sirolimus for Autoimmune Disease of Blood CellsCompletedNCT00392951Phase 1/21 country
- Feasibility Study of Unfractionated Heparin in Acute Chest SyndromeTerminatedNCT02098993Phase 21 country
- The Role of Microparticles as a BiomarkerWithdrawnNCT026266631 country
- Long-Term Therapy With Ribavirin for Chronic Hepatitis CCompletedNCT00001854Phase 41 country
- Long Term Effects of Erythrocyte LysisCompletedNCT008426211 country
- Immunoglobulin Dosage and Administration Form in CIDP and MMNCompletedNCT021115901 country
- Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia in Northern IsraelCompletedNCT009719841 country
- Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3CompletedNCT00056862Phase 41 country
- Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney DiseaseCompletedNCT00028093Phase 41 country
- Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic AnemiaCompletedNCT01134432Phase 31 country
- Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal HemoglobinuriaStatus unknownNCT01642979Phase 21 country
- Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)Status unknownNCT01760096Phase 21 country
- Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.Status unknownNCT01579110Phase 21 country